Strategic shift SeqOnce Biosciences has evolved from a standalone life science tools developer to a portfolio-driven ecosystem with technologies now being developed and commercialized by the G3 Genomics portfolio, indicating a potential collaboration or cross-sell path with Bandit Bio and other portfolio companies.

New assay expansion Recent launch of the RT-qPCR Measles Panel and ongoing pathogen assay suite expansion present opportunities to cross-sell complementary qPCR and diagnostic kits to existing customers in infectious disease surveillance and clinical research.

Facility growth History of facility expansion in Carlsbad and continued geographic presence in the U.S. suggest capacity to support pilot orders, trials, or localized OEM partnerships; leverage this for regional sales outreach and logistics planning.

COVID and SARS-CoV-2 lineage work Earlier and ongoing commitments to SARS-CoV-2 related kits and variant detection indicate a sustained emphasis on viral diagnostics; identify buyers in clinical labs, public health, and contract research organizations requiring validated RT-qPCR workflows and controls.

Revenue range and market fit With reported revenue in the 1-10 million range and a focus on qPCR and NGS library prep tools, there is potential for upsell of higher-throughput kits, controls, and streamlined library prep solutions to mid-market genomics labs seeking scalable workflows.